SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Revolutions Medical Corporation (OTCBB: RMCP) $0.49. Announced Monday after market close detailed performance and aesthetic improvements to its flagship Rev Vac syringe, and debuted a highly informative product demonstration video.
"We will unveil the long-anticipated enhanced design of the Rev Vac safety syringe on our website stated Company CEO Ron Wheet. "The improvements increase substantially the readability of the fluid levels and the accuracy of the fluid draw. A distinctive color scheme makes the Rev Vac syringe easily identifiable. Simple to read pictograms on each packet insert allow for reduced training needs while improving correct usage. Combined, these feature enhancements dramatically escalate our competitive advantage in the space, and ensure a product that not only costs less, but significantly outperforms many established products.
"And with our new animated demonstration video, we now have an engaging and educational resource that will serve as both an exceptional sales piece and an unparalleled training tool. At time of product launch, we will feature a dynamic multi-media marketing platform that will further set Revolutions Medical apart as the leading safety syringe company."
The Rev Vac safety syringe received FDA 510K clearance earlier this year; this redesign does not impact that clearance.
What They Do: Revolution Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.
NxStage Medical (Nasdaq: NXTM) Announced Monday after market close its wholly-owned subsidiary, Medisystems Corporation, has signed a new three-year product supply agreement with Reliant Renal Care, Inc., for the delivery of Streamline airless blood tubing sets, as well as MasterGuard® safety needles with FingerShield® to Reliant's dialysis center network.
"With nearly two million treatments to date, our Streamline blood tubing set continues to gain traction in the market. As such, we are very pleased that Reliant has selected both Streamline and our MasterGuard needles for integration into their in-center operations," stated Mark S. Florence, Vice President and General Manager of Medisystems Corporation. "This combination of innovative and proven technologies underscores our commitment to bring added clinical and economical value to our customers for the benefit of dialysis patients."
What They Do: NxStage Medical is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure.
The Lubrizol Corporation (NYSE: LZ) $66.87. Announced Monday after market close that it is raising its earnings guidance for 2009 to a range of $5.87 to $6.17 per diluted share, including restructuring and impairment charges of $0.23 per diluted share. Excluding these charges, guidance for adjusted earnings is in the range of $6.10 to $6.40. This revised guidance reflects improving volume trends in the current quarter, the company's ongoing margin management and its maintenance of cost reduction initiatives. The company's prior earnings guidance for 2009, last updated on July 30, 2009 was in the range of $5.47 to $5.77, including restructuring and impairment charges, and $5.70 to $6.00 per diluted share excluding restructuring and impairment charges.
What They Do: The Lubrizol Corporation is an innovative specialty chemical company that produces and supplies technologies that improve the quality and performance of our customers' products in the global transportation, industrial and consumer markets.
XL Capital Ltd (NYSE: XL) $16.94. Announced Monday after market close that the Company and its Chief Financial Officer, Brian Nocco, have agreed that Mr. Nocco will leave XL effective after year end. Mr. Nocco, who has served as XL's CFO since July 2007, has agreed to remain as CFO until year end to ensure a smooth transition. The Company has initiated a search for a successor to Mr. Nocco.
What They Do: XL Capital Ltd, through its operating subsidiaries, is a leading provider of global insurance and reinsurance coverages to industrial, commercial and professional service firms, insurance companies and other enterprises on a worldwide basis.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
